Author

Oscar Hou In Chou

Imperial College LondonORCID 0000-0001-7058-4708Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:gene regulatory network inference· 1 Research Focus:GWAS / association mapping· 1 Assay:GWAS summary statistics· 1

Frequent Co-Authors

Aaron Mamane-LogsdoniD· 1 shared Adam C. T. GillmaniD· 1 shared David A. MatthewsiD· 1 shared Gary TseiD· 1 shared Guoliang LiiD· 1 shared I’ah Donovan-BanfieldiD· 1 shared Isabelle Zane· 1 shared Jiajun HuangiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Aaron Mamane-LogsdonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologyJournal of General VirologyPeer-reviewedAug 26, 2025

A direct RNA-seq-based EBV Latency Transcriptome Offers Insights into the Biogenesis of EBV Gene Products.

Aaron Mamane-Logsdon, Isabelle Zane, June See Chong…·Robert E. White

This paper uses long-read RNA-seq to analyze EBV transcriptomes in LCLs, identifying new splicing variants, polyA sites, and transcript structures, and provides tools and annotations for future studies.

4 citations

humanlong-read sequencing

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintSep 15, 2024

Genetic associations between SGLT2 inhibition, DPP4 inhibition or GLP1R agonism and prostate cancer risk: a two-sample Mendelian randomisation study

Lin Shen, Yifan Yang, Lei Lü…·Jiandong Zhou

This paper uses Mendelian randomization to find that SGLT2 and DPP4 inhibition are associated with reduced prostate cancer risk, but GLP1R agonism is not.

DOI 10.1101/2024.09.15.24313695

humanGWAS summary statistics

𝕏 PostBluesky